InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,855.60
(
0.05%
)
Dow Jones
39,375.87
(
0.00%
)
Brent Oil
85.76
(
-0.87%
)
Bitcoin
57,053.93
(
2.15%
)
Post# of 252506
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119984
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech_researcher post# 213272

Sunday, 08/27/2017 12:36:57 PM

Sunday, August 27, 2017 12:36:57 PM

Post# of 252506
NVS’ own PR on CANTOS study of Ilaris (a/k/a ACZ885/canakinumab):

https://www.novartis.com/news/media-releases/novartis-phase-iii-cantos-study-demonstrates-targeting-inflammation-acz885

Note: CANTOS top-line results were reported in June (#msg-132398529), but the full dataset was presented for the first time this weekend.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up